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ABSTRACT
Location analysis for estrogen receptor-a (ERa)-
bound cis-regulatory elements was determined in
MCF7 cells using chromatin immunoprecipitation
(ChIP)-on-chip. Here, we present the estrogen
response element (ERE) sequences that were
identified at ERa-bound loci and quantify the inci-
dence of ERE sequences under two stringencies of
detection: <10% and 10–20% nucleotide deviation
from the canonical ERE sequence. We demonstrate
that  50% of all ERa-bound loci do not have a
discernable ERE and show that most ERa-bound
EREs are not perfect consensus EREs. Approxi-
mately one-third of all ERa-bound ERE sequences
reside within repetitive DNA sequences, most
commonly of the AluS family. In addition, the 3-bp
spacer between the inverted ERE half-sites, rather
than being random nucleotides, is C(A/T)G-enriched
at bona fide receptor targets. Diverse ERa-bound
loci were validated using electrophoretic mobility
shift assay and ChIP-polymerase chain reaction
(PCR). The functional significance of receptor-
bound loci was demonstrated using luciferase
reporter assays which proved that repetitive
element ERE sequences contribute to enhancer
function. ChIP-PCR demonstrated estrogen-
dependent recruitment of the coactivator SRC3 to
these loci in vivo. Our data demonstrate that ERa
binds to widely variant EREs with less sequence
specificity than had previously been suspected and
that binding at repetitive and nonrepetitive genomic
targets is favored by specific trinucleotide spacers.
INTRODUCTION
Estrogens are steroid hormones that play critical roles in
the initiation, development and metastasis of breast and
uterine cancers (1). The estrogen (E2) response in breast
cancer cells is predominantly mediated by the estrogen
receptor-a (ERa/NR3A1), a ligand-activated transcrip-
tion factor (2). ERa regulates the transcription of target
genes through direct binding to its cognate recognition
sites, known as estrogen response elements (EREs), or
by modulating the activity of other DNA-bound tran-
scription factors at alternative DNA sequences (3–10).
These functions have recently been demonstrated to
occur across great genomic distances (tens to hundreds
of kilobases) and even across chromosomes (11–20).
Rapid, ‘non-genomic’ estrogen eﬀects have also been
described, involving plasma membrane and cytosolic
eﬀects of the hormone that may or may not be mediated
by the classical estrogen receptors and their various
isoforms (11,12).
We and others have recently analyzed targets of
estrogen signaling in MCF7 breast cancer cells by
performing genome-wide binding site mapping of
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that we identiﬁed ( 80%) were located >10kb from
any annotated transcription start site (TSS) (13). Nye
and colleagues (17) demonstrated that ERa displays the
ability to alter large-scale chromatin structure when
tethered or directly bound to DNA. Together, these obser-
vations imply long-range interactions between ERa-
bound regulatory regions and target promoters, closely
tied to higher-order chromatin conformational changes
such as chromatin decondensation, compaction, and
territory formation (17–22). Some chromatin changes are
initiated by unliganded ERa (Apo-ERa) and/or the
pioneer factor forkhead box A1 (FOXA1/HNF3a) and
may maintain gene targets in a state that is poised for
rapid gene activation upon stimulation with estrogen
(19,23,24).
Estrogen receptor dimers bind to the canonical 13-bp
ERE, GGTCAnnnTGACC, a palindromic inverted repeat
(IR) separated by any three nucleotides (nnn) originally
identiﬁed from conserved sequence alignments of the
estrogen-sensitive Xenopus laevis vitellogenin and the
chicken apo-VLDL genes (25,26). The consensus ERE
sequence was subsequently extended to a 15-bp palin-
drome (AGGTCAnnnTGACCT) when the ﬂanking
sequences were noted to contribute to dimer-binding
aﬃnity (27). Once full human genomic sequence data
became available, several groups of investigators
combined bioinformatic approaches (principally position
weight matrices, or PWMs) with large-scale gene expres-
sion studies in order to identify E2-responsive and
possibly ERa-regulated genes of interest (28–31). The
PWMs were designed using fewer than 20 natural EREs.
These EREs were all promoter-proximal elements located
< 2kb from the transcription start sites for their respec-
tive genes (27).
The extent to which functional EREs might deviate
from the known examples has remained uncertain.
Although it was recognized that functional EREs gener-
ally did ‘not’ conform to the consensus sequence, in vivo
(32,33), experimental data indicated decreased ERa
binding to variant ERE sequences in vitro (28,34). In
fact, single gene promoter analyses identiﬁed functional
EREs containing single- double- and triple-nucleotide
substitutions from the consensus ERE sequence (27,33).
Even when stringent nucleotide sequence criteria are
applied, many more putative EREs exist in the human
genome than are bound by ERa in any given cell type
(13,14). For example, computational analysis of the
human and mouse genomes, allowing up to 2-bp substi-
tutions from the consensus ERE, revealed >17000
and >15000 possible EREs within 15kb of annotated
transcription start sites, respectively (28). An unbiased
analysis of the published human genome reveals 2310
perfect EREs (13-bp core ERE sequences), 49803 ERE
sequences with only 1-bp deviation from the consensus
sequence and 265482 loci that deviate by only two
mismatches. Yet, studies in MCF7 cells have indicated
that only  1000–10000 loci are bound by ERa in
response to estrogen treatment (13–16,35). Importantly,
there is substantial cell type-speciﬁc determination of
ERa binding sites and this correlates with cell type-speciﬁc
post-translational histone modiﬁcations at receptor-
bound sites (36). Distinguishing histone modiﬁcations
that are necessary for gene activation or repression from
chromatin marks that are associated with these respec-
tive processes, but not necessarily causative, remains
challenging.
Notably, DNA-binding aﬃnity of transcription factors
is not the sole determinant of transcription factor
function. There is increasing evidence that multiple
ERa-bound loci with varying DNA-binding aﬃnities can
cooperate to form a productive cis-regulatory module
(28,35–39). Low-aﬃnity receptor–DNA interactions may
remain transcriptionally productive in some enhancer
contexts. Additional determinants of receptor function
may include local non-ERE DNA sequences, DNA
methylation status, regional chromatin composition and
post-translational modiﬁcations, cofactor concentrations
and the nature of the receptor ligand that is engaged
(13,19,24,35,40–42).
Once directly bound to a cis-regulatory element, the
ﬁrst zinc ﬁnger of the ERa DNA-binding domain
(DBD) binds in the major groove of the DNA double
helix and mediates the sequence-speciﬁc interaction of
the receptor dimers at each half site of the ERE.
Estrogen receptor amino acid residues interact with
select DNA bases via hydrogen bonding and van der
Waals interactions (43,44). The extent of receptor inter-
actions with variant DNA sequences has never been
determined on a large scale. Rather, transcription
factor–chromatin association has traditionally been deter-
mined one element at a time, limiting the statistical power
to characterize variations in cis-regulatory elements.
In order to comprehensively identify ERa-bound
targets in MCF7 cells, and to address the question of
ERE sequence speciﬁcity, we recently employed chromatin
immunoprecipitation (ChIP) experiments with whole
genome DNA arrays (i.e. ChIP-on-chip) (13). Here,
these data are combined with data from a similar study
conducted by the Brown lab (14) in order to develop a list
of high-conﬁdence ERa-bound loci. These immunopre-
cipitated chromatin fragments are likely to contain true
estrogen responsive elements because (i) they were
cross-linked to ERa in living cells (directly or via protein
intermediaries), and (ii) they were detected by two inde-
pendent laboratories.
We present the ERE sequences that were identiﬁed
within 1017 high-conﬁdence ERa-bound ChIP sites and
quantify the prevalence of base-pair variations from
the consensus ERE sequence. Approximately 50% of all
ERa-bound loci do not have a discernable ERE and likely
represent sites of ERa tethering via other transcription
factors or contain atypical estrogen response elements
(i.e. tandem half-ERE sites). Further, most ERa-bound
cis-regulatory elements are not consensus EREs and the
most commonly bound element in MCF7 cells is not a
consensus ERE. We demonstrate that many ERa-bound
sites have two or more ERE-like sequences within 2kb
of the center of the ChIP site, suggesting additive
or synergistic potential of tandem ERE sequences. We
demonstrate that the 3-bp spacer between the inverted
ERE half-sites, rather than being random nucleotides,
2356 Nucleic Acids Research, 2010,Vol.38, No. 7is enriched for selected sequences at in vivo receptor
targets. Finally, many functional EREs reside within
repetitive DNA elements, particularly of the Alu family
of repetitive DNA sequences, and these sequences are
likely to contribute to the estrogen-signaling cascade in
MCF7 cells.
MATERIALS AND METHODS
Cell Culture
MCF7 cells (ATCC) were grown as described (45).
Cells were changed to E2-depleted, phenol red-free
media consisting of MEM alpha (Gibco) with 10%
charcoal/dextran-stripped calf serum, insulin, penicillin
G, streptomycin and L-glutamine (all Gibco), for 72h
prior to treatments. Where indicated, treatments
included vehicle control (100% EtOH) and estradiol
(10 or 100nM, Sigma). Telomerase-immortalized
Human Endometrial Stromal Cells (HESC cells), a
generous gift from Dr. Graciela Krikun, were grown in
the same media used for the MCF7 cells. HESC cells have
normal chromosome numbers and structures (46).
Preparation of nuclear extracts and electrophoretic
mobility shift assay
HESC nuclear extracts (NEs) were puriﬁed using NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce),
according to the manufacturer’s instructions. Human
embryonic stem cells (HESCs) have no demonstrable
ERa activity using sensitive luciferase reporter assays
and no ERa protein detected by western blot analysis
(data not shown). However, HESC cell nuclei have
cofactors that promote the binding of recombinant ERa
(rERa, Aﬃnity Bioreagents) to target DNA in electro-
phoretic mobility shift assay (EMSA) and these factors
enhance binding when compared to recombinant ERa
alone. EMSA experiments were therefore conducted
using HESC NEs combined with rERa. Protein determi-
nations were performed using the Micro BCA assay
(Pierce) and 5mg of NE (with protease inhibitors,
Roche) plus rERa (400fmol) were run in each lane of a
5% acrylamide gel in TBE/glycerol buﬀer.
Oligonucleotide probes were labeled using the Biotin 30
End DNA Labeling Kit (Pierce). Each Biotin-labeled
probe was used at 20fmol/lane and binding reactions
were performed per LightShift Chemiluminescent EMSA
Kit instructions (Pierce). For super-shift assays, relevant
antibody was used as indicated (400ng/reaction):
anti-ERa Ab-10 (LabVision) and anti Sp1 H-225
sc-14027 (Santa Cruz). A complete list of oligonucleotide
sequences used as probes for EMSA is presented in the
Supplementary Table S1.
ChIP—polymerase chain reaction
ChIP was performed as previously described (13). Brieﬂy,
MCF7 Cells were E2-deprived for 3 days and then treated
with 100nM E2 or vehicle for 45min (19,41). Approxi-
mately 5 10
6 cells per ChIP were cross-linked with 1%
formaldehyde for 10min at 37 C then quenched with
125mM glycine. The cells were washed with cold
phosphate-buﬀered saline (PBS) and scraped into PBS
with protease inhibitors (Roche). Cell pellets were
resuspended in ChIP lysis buﬀer [1% sodium dodecyl
sulfate (SDS), 10mM ethylenediaminetetraacetic acid
(EDTA), 50mM Tris–HCl (pH 8.1)] and sonicated
(Fisher Sonic Dysmembrinator) to produce sheared
chromatin with average length 500bp. The sheared
chromatin was submitted to a clariﬁcation spin and the
supernatant then used for ChIP or reserved as ‘Input’.
Antibodies used were anti-ERa (Ab-1, Ab-3 and Ab-10
from Lab Vision and MC-20 from Santa Cruz) and
anti-SRC3 (ab2831 Abcam). Quantitative PCR was per-
formed using iQ-SYBR Green Master Mix (Biorad) in a
Biorad Opticon 2 cycler. PCR reactions were assembled
in triplicate and the enrichment of target sequences in
ChIP material was calculated relative to 28S ribosomal
RNA coding sequence as a reference. PCR values for
E2-treated cells were then normalized to control
(E2-depleted) cells. Forward and reverse primer sequences
used for ChIP-PCR were designed to hybridize to unique
nonrepetitive genomic sequences after excluding repetitive
DNA sequences using RepeatMasker V3.1. Primers are
listed in the Supplementary Table S1.
Luciferase reporter assays
Luciferase reporter assays were performed using the
Luciferase Assay System (Promega) according to the
manufacturer’s instructions. Potential ERE-containing
regulatory elements were cloned into pGL2-Promoter
(Promega) and transfected into MCF7 cells using the
TransIT-LT1 Transfection Reagent (Mirus). Cotrans-
fection with a b-galactosidase-expressing plasmid
(Promega) enabled normalization of transfection eﬃciency
across samples using a b-galactosidase assay kit (Promega)
according to the manufacturer’s instructions.
Cloning and mutagenesis
PCR cloning was performed using PCR ampliﬁcation of
ERa-bound genomic loci from HESC cell genomic DNA
which was prepared using the Genomic DNA Extraction
kit (Qiagen) according to the manufacturer’s instructions.
PCR products, average length 776bp, were ligated into
the reporter construct pGL2-promoter (Promega) at
50-KpnI and 30-XhoI sites, for use in Luciferase Reporter
assays. Mutagenized reporter constructs were prepared
using the Genetailor Site-Directed Mutagenesis System
(Invitrogen) according to the manufacturer’s instruc-
tions. All clones and subclones were conﬁrmed by DNA
sequencing. Primers used for genomic locus ampliﬁcation,
subcloning, and site-directed mutagenesis are available
upon request.
Computational detection of ERE aequences
Genome-wide location analysis for ERa, and
E2-dependent gene expression proﬁling, were performed
by two independent groups as previously described
(13,14). The 1017 ERa-bound genomic loci common to
both data sets (shared loci deﬁned as falling within
1kb of the center of each locus) were interrogated for
Nucleic Acids Research,2010, Vol.38, No. 7 2357ERE-like sequences. Starting at the center of each high-
conﬁdence ERa-bound locus, we extracted genomic
sequences 1kb in each direction (hg 18, build 36.1). As
the chromatin shear size in ChIP experiments was
optimized to average  500bp, we estimated that inter-
rogating sequences of average size 2kb would have a
reasonable likelihood of capturing most sequences
directly bound by ERa in the ChIP assays. Transcription
Element Search Software (TESS) was used to identify
ERE sequences (47). Default settings were used with vari-
ation in Maximum Allowable String Mismatch of 10%
and 20%. The TESS software will identify binding sites
using consensus strings from the TRANSFAC, JASPAR,
IMD and CBIL-GibbsMat databases. Repetitive DNA
elements were determined using RepeatMasker V3.1 at
the default settings (http://www.repeatmasker.org).
Statistics
Comparisons between two groups were made using
a two-tailed Student’s t-test with P-values indicated.
Statistical analysis of the base pair distributions in the
ERE spacer sequences was performed using the
Pearson’s chi-square to test for goodness of ﬁt.
RESULTS
EREs found at 1017 high-conﬁdence ERa-bound loci
We recently performed location analysis for ERa in
MCF7 cells using ChIP-on-chip with whole genome
tiling arrays and combined these data with gene expression
proﬁling in response to E2 exposure (13). This work
resulted in an expanded understanding of pathways
involved in E2-mediated cellular proliferation and
identiﬁed the E2-responsive chromatin protein, H2A.Z,
as a predictor of breast cancer progression. The location
analysis identiﬁed 1615 genomic targets of ERa and
revealed that the majority ( 80%) of ERa-bound loci
reside >10kb from any annotated transcription start
site. Further, of the E2-regulated genes that were
identiﬁed, only 5.1% had an ERa-bound locus within
10kb of the transcription start site, while 39% had a
ChIP site within 200kb of the TSS. Of 1615 loci that
were bound by ERa in our analysis, 1017 ( 60%) were
also detected by the Brown group (14). A list of the
genomic coordinates for these highest-conﬁdence
ERa-bound loci appears in the Supplementary Table S2.
ChIP-on-chip data were validated by ChIP-PCR for 17
sites and revealed E2-dependent recruitment (>2-fold)
of ERa at all of the loci that were tested (Figure 1, for
genomic coordinates see Table 2). All primers used for
ChIP-PCR were designed to hybridize to unique nonrepe-
titive genomic sequences after excluding repetitive DNA
sequences using RepeatMasker V3.1.
Using Transcription Element Search Software (TESS)
(47), we performed an analysis of the 1017 ERa-bound
loci (average length 2kb) for the presence of ERE
sequences. This analysis was performed at two stringencies
of ERE detection:  10% nt deviation ( 2 mismatched
residues within the core 15-bp ERE), and 10–20%
nucleotide divergence (3–4 mismatched residues) from
the 15-bp consensus ERE sequence (AGGTCAnnnTGA
CCT). We identiﬁed a total of 646 ERE sequences
(Supplementary Table S3) from 509 ERa-bound loci,
indicating that  50% of receptor-bound sites did not
have a discernable ERE sequence; 391 ( 77%) of the
ERE-containing ChIP sites contained a single ERE
sequence, 101 ( 20%) contained two distinct ERE
sequences and 17 loci ( 3%) contained three or more
distinct ERE sequences within 2kb of the center of their
respective ChIP sites.
ERa-bound loci are highly enriched for
non-consensus EREs
The sequence requirements for ERa binding to chromatin
in vivo are surprisingly ﬂexible. Table 1 demonstrates the
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Figure 1. ChIP-PCR validation of ERa-bound loci. ERa-bound loci determined by ChIP-on-chip were interrogated for E2-dependent ERa binding
using quantitative ChIP-PCR (for genomic coordinates see Table 2). MCF7 cells were treated with E2 (100nM) or vehicle (EtOH) for 45min. ChIP
was performed using antibodies against ERa. Quantitative PCR using genomic primers employed the 28S rRNA coding sequence as internal
reference. Shown are E2-treated values normalized to control values. ERa was not recruited to an ERE-less and ChIP-on-chip negative locus
dubbed ERE(–). Similar studies using genomic PCR primers for the known E2-responsive genes TFF1 and CTSD demonstrated rapid recruitment of
ERa to these enhancer regions in response to E2. ChIP-PCR targeting 17 additional loci similarly revealed E2-dependent enrichment (>2-fold) of
ERa at all sites. Values are the average of three experiments with SEM. Oligonucleotide sequences are presented in Supplementary Table S1.
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sequence for each stringency assayed (A and B in
Table 1). The base frequencies are pooled for all EREs
that were detected (0–20% nt divergence from consensus)
(C in Table 1). At all stringencies assayed, the 13-bp core
bases were more highly conserved than the ﬂanking
sequences located at positions 1 and 15 of the EREs.
When we considered an additional 15bp of ﬂanking
sequence in the 50 and 30 directions from the EREs no
conservation of nucleotide sequences was found indicating
that the ERE motif does not extend beyond these 15 bases
(data not shown).
It is noteworthy that, even at high stringency of detec-
tion, most possible single base substitutions were detected
in our dataset. These data are consistent with in vitro data
(EMSAs) indicating that all single base-pair deviations
from consensus are capable of binding to the estrogen
receptor, although with variable aﬃnity (28). When
ERE detection criteria were relaxed to permit 10–20%
base divergence from the consensus sequence, all forms
of nucleotide substitutions were permissive for receptor
binding though some substitutions were rarer than
others (B and C in Table 1). For example, from all
EREs that were detected, position 2 is rarely (<1%)
cytosine, whereas position 12 is cytosine in 9.1% of
EREs (C in Table 1).
Ignoring the trinucleotide spacer sequence, 348 diﬀerent
ERE sequences were detected from the group of 646
total EREs (Supplementary Table S4). There was equal
representation of an imperfect ERE (16 examples of GG
GTCAnnnTGACCT) and a perfect consensus ERE
(16 examples of AGGTCAnnnTGACCT) (Supplementary
Table S4). Excluding analysis of the less-conserved posi-
tions 1 and 15 in the 646 ERE sequences that we identiﬁed,
we detected 51 ( 8%) perfect core consensus EREs (GGT
CAnnnTGACC). Thus, of the 2310 perfect consensus
ERE sequences detected in the published sequence of the
human genome, our highest-conﬁdence location analysis
revealed ERa occupancy at only 51 (2.2%) of these sites
in MCF7 cells. These data demonstrate that ERa binds
to widely variant EREs in MCF7 cells and that many
‘perfect’ EREs are not receptor-bound in these cells
under these E2-stimulated culture conditions.
The trinucleotide spacer sequences of ERa-bound EREs
are conserved residues
The trinucleotide spacer sequence between the two ERE
half sites does not make important base contacts with the
estrogen receptor’s DBD (43,44,48) and has historically
been described as nnn (meaning that any 3-bp sequence
will suﬃce). Our data indicate that, at all stringencies of
ERE detection, the trinucleotide spacer is conserved
at receptor-bound EREs. Speciﬁcally, positions 7–9 are
preferentially C(A/T)G at ERa-bound loci; this spacer
sequence is found at more than 40% of EREs (Supple-
mentary Table S4 and Table 1). When compared to
the expected equal distribution of bases at each position,
Table 1. Base frequency matrix as a function of nucleotide position for ERE sequences detected
A. Stringency 0-10%, 164 total EREs, 31 (19%) of EREs in repetitive elements.
Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
%A 77.4% 3.0% 0.6% 2.4% 0.6% 94.5% 14.0% 28.7% 14.6% 1.8% 1.8% 87.8% 3.0% 4.9% 6.1%
%C 3.0% 0.0% 1.8% 2.4% 94.5% 1.2% 43.3% 17.1% 24.4% 0.0% 1.2% 7.3% 93.9% 91.5% 13.4%
%G 15.2% 90.9% 97.0% 7.3% 1.8% 1.8% 25.0% 22.6% 49.4% 0.6% 94.5% 2.4% 0.0% 0.0% 3.7%
%T 4.3% 6.1% 0.6% 87.8% 3.0% 2.4% 17.7% 31.7% 11.6% 97.6% 2.4% 2.4% 3.0% 3.7% 76.8%
B. Stringency 10-20%, 482 total EREs, 174 (36%) of EREs in repetitive elements.
Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
%A 76.6% 8.7% 5.4% 5.8% 2.1% 75.9% 12.9% 36.7% 11.8% 5.0% 12.9% 82.6% 3.9% 6.6% 6.4%
%C 3.1% 1.2% 11.4% 6.2% 74.9% 3.9% 57.1% 13.7% 17.8% 9.1% 4.8% 9.8% 75.7% 86.1% 20.1%
%G 16.2% 81.5% 78.8% 7.1% 3.9% 15.6% 17.6% 18.0% 58.3% 4.1% 80.1% 3.1% 17.2% 1.2% 3.5%
%T 4.1% 8.5% 4.4% 80.9% 19.1% 4.6% 12.4% 31.5% 12.0% 81.7% 2.3% 4.6% 3.1% 6.0% 69.9%
C. Stringency 0-20%, 646 total EREs, 205 (32%) of EREs in repetitive elements.
Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
%A 76.8% 7.3% 4.2% 5.0% 1.7% 80.7% 13.2% 34.7% 12.5% 4.2% 10.1% 83.9% 3.7% 6.2% 6.3%
%C 3.1% 0.9% 9.0% 5.3% 79.9% 3.3% 53.6% 14.6% 19.5% 6.8% 3.9% 9.1% 80.3% 87.5% 18.4%
%G 15.9% 83.9% 83.4% 7.1% 3.4% 12.1% 19.5% 19.2% 56.0% 3.3% 83.7% 2.9% 12.8% 0.9% 3.6%
%T 4.2% 7.9% 3.4% 82.7% 15.0% 4.0% 13.8% 31.6% 11.9% 85.8% 2.3% 4.0% 3.1% 5.4% 71.7%
Transcription Element Search Software (TESS) was used to analyze 1017 ERa-bound loci at two diﬀerent stringencies of detection. High stringency
(0–10% deviation from the consensus ERE sequence) and low stringency (10–20% deviation from the consensus ERE) results are shown in A and B,
respectively. These data are pooled (in C) to reveal a total of 646 ERE sequences residing within 509 receptor-bound loci. The distribution of ERE
sequences within repetitive elements is indicated for each stringency. The trinucleotide spacer sequences are non-randomly distributed at all
stringencies of detection (see main text) even when repetitive element EREs are excluded from the analysis (see Supplementary Table S5). Bold
values (also highlighted) are the most common bases found at each position of the detected EREs and the trinucleotide spacer sequences are
indicated in italics.
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sequences at positions 7–9 was indicated by the chi-square
test with P-values of 1.9E–14, 2.04E–96 and 7.97E–106 for
stringencies 0–10% (A), 10–20% (B) and 0–20% (C),
respectively (Table 1). The observed conservation of the
central triad sequence remained even when all repetitive
element EREs were excluded from the analysis (Supple-
mentary Table S5). While the molecular justiﬁcation
for this triad sequence preference is unclear, these data
suggest that the 3-bp spacer has functional signiﬁcance,
possibly modulating ERa-ERE binding and subsequent
transcriptional responses.
To identify ERE sequences which might distinguish
between promoter-proximal and distal enhancer func-
tions, we further analyzed our gene-expression data
previously integrated with genome-wide location analysis
for ERa (13). Of the E2-regulated genes that were
identiﬁed, only 5.1% had an ERa-bound locus within
10kb of the transcription start site (13). From our list of
computationally detected ERE sequences (Supplementary
Table S3), we identiﬁed 13 EREs that reside within the
promoter regions of E2-regulated genes (deﬁned as +/–
1kb from the annotated transcription start site for each
gene). Analysis of EREs residing within E2-regulated
gene promoters demonstrated similar enrichment for the
C(A/T)G trinucleotide spacer sequence (data not shown).
This observation suggests that the conservation of the
C(A/T)G trinucleotide spacer sequence exists for both
proximal promoter and distal enhancer EREs and does
not distinguish between these functions in MCF7 cells.
We next focused our analysis on the 103 ERa-bound
ERE sequences that reside within 100kb of an
E2-regulated gene (13). This analysis compared estrogen-
stimulated versus estrogen-repressed genes and indicated
similar enrichment of the C(A/T)G trinucleotide spacer
sequence at the ERE sequences of these respective loci
(data not shown). Thus, our data do not support a role
for the trinucleotide spacer sequence in distinguishing
between E2-stimulated and E2-repressed gene targets in
MCF7 cells.
Many EREs reside within repetitive DNA elements
In our analysis, we found that a considerable proportion
of EREs lay within repetitive element sequences
(Supplementary Table S3). Depending upon the strin-
gency of detection, between 19% and 36% of EREs
resided within repetitive (i.e. repeat-masked) DNA
elements. The most common repetitive element harboring
ERE-like sequences was the Alu retrotransposable
element (a member of the short interspersed element,
or SINE, family). However, we detected EREs within
a broad range of repetitive sequences including non-Alu
SINE elements, long interspersed elements (LINEs),
DNA transposable elements, long terminal repeat (LTR)
retrotransposons, non-LTR retrotransposons and micro-
satellites [a.k.a. simple sequence repeats (SSRs)].
One group initially reported the existence of an ERE
within an Alu sequence near the BRCA1 gene (49).
Further study of their sequence revealed that this
putative-ERE was non-functional in an ERa-containing
and E2-responsive model cell system, calling into
question their initial studies which used a hepatocyte cell
system that was engineered to overexpress ERa (50).
Additional ﬁndings in MCF7 cells ultimately lead the
authors to conclude that this putative Alu-ERE did not
function as a classical ERE and was unlikely to be an
ERa-responsive enhancer (50). Our recent ChIP-on-chip
data similarly do not support BRCA1 to be a direct ERa
gene target in MCF7 cells (13).
The canonical 280-bp Alu sequence is composed of
two monomers, derived from the 7SL RNA gene,
separated by an adenosine rich connector (Figure 2A).
Each monomer present in the progenitor Alu family
sequences has an ERE-like sequence which, with
mutation accumulation, might reasonably form a func-
tional ERE (Figure 2B) (51–53). The majority of Alu-
ERE elements that were detected from our ChIP sites
resided within 30 monomer sites of Alu elements
(Supplementary Table S3).
Selected repetitive element EREs are capable of binding
to ERa, in vitro
Given the widespread variations in ERE sequences
detected from our ChIP-positive loci, we tested two
ChIP-positive repetitive element EREs in order to illus-
trate that our variant ERE sequences (complete with
their respective trinucleotide spacer sequences) are
capable of binding to ERa in vitro. EMSAs indicated
that the 30 ERE sequence of locus B68 (a MIRb
element) and the 50 ERE sequence of locus D66 (also
a MIRb element) bind speciﬁcally to ERa (Figure 3).
Speciﬁc binding of DNA probes to ERa-containing
protein complexes was indicated by anti-ERa antibody-
mediated supershift (for the consensus ERE probe) or
loss of binding (for the two repetitive DNA element
probes). Nonspeciﬁc antibody (anti-Sp1) had no eﬀect
on ERa binding to consensus or B68 EREs but demon-
strated some inhibition of protein binding to the
D66-ERE, indicating that Sp1 may participate in the
ERa-containing protein complexes that bind to this
element. Sp1 is a ubiquitous transcription factor which
can physically interact with ERa at imperfect and
half-site EREs spaced near Sp1-REs (10,54). Such
compound regulatory elements generally include GC-rich
sequences similar to the probe for D66-ERE, which was
designed entirely based upon the D66-ERE genomic
sequence. Together, these data provide in vitro support
for the conclusion that repetitive DNA element EREs
are able to recruit ERa binding in vivo.
Selected repetitive element EREs mediate ERa-dependent
transcriptional responses
Our observation that ERa-bound Alu elements represent
a class of repetitive DNA elements that contain EREs
prompted us to perform functional testing of these and
other repetitive element EREs. We cloned a representative
sampling of ChIP-positive, ERE-containing genomic loci
(summarized in Table 2) to test these for E2-dependent
enhancer function in luciferase reporter assays. Our
loci were selected to include nonrepetitive element and
2360 Nucleic Acids Research, 2010,Vol.38, No. 7repetitive-element ERE sequence(s). Some cloned loci con-
tained more than one ERE sequence. The majority of
loci resided <250kb from at least one E2-responsive
gene as determined by our prior gene expression proﬁling
(13) and as reported in the Estrogen Responsive Genes
Database (55).
Cloned loci demonstrated transcriptional responses that
ranged from zero to strong E2-dependent responses in
luciferase reporter assays. Figure 4 displays the responses
of several cloned loci that demonstrated strong enhancer
functions in response to E2. Locus D54 is near the
E2-responsive gene MSX2 and harbors three ERE
sequences (indicated above the bars in the graph). The
third ERE at this locus resides in an MIR-element
[SINE family of retrotransposable elements (Table 2)]
and is indicated by the red font. Mismatches from consen-
sus ERE sequences are indicated by lower case lettering.
Site-directed mutagenesis of each ERE (wherein both
half-sites are replaced with tttttt) indicated that the ﬁrst
and second EREs are each necessary for enhancer
function as loss of either site (i.e. E1M and E2M) results
in loss of reporter activity (Figure 4A). Mutation of the
third site (E3M), the MIR-ERE, resulted in nearly 3-fold
diminishment of enhancer function, indicating that it
contributes to overall enhancer function of the cloned
genomic fragment. We conclude that the MIR-ERE is
necessary for full enhancer activity of the D54 locus in
response to E2.
Figure 4B indicates the transcriptional response of locus
B68 which harbors two repetitive element ERE sequences
(indicated by red font), the ﬁrst residing in an Alu element
and the second in a MIRb element (Table 2). While
Consensus AluSc sequence: 
5'-ggccgggcgcggtggctcacgcctgtaatcccagcactttgggaggccgaggcgggcGGATCAcg
AGGTCAagagatcgAGacCAtccTGgCCaacatggtgaaaccccgtctctactaaaaatacaaa
aattagctgggcgtggtggcgcgcgcctgtagtcccagctactcgggaggctgaggcaggagaatcgcttg
aacccgggaggcggAGGTtgcagTGAgCcgagatcgcgccactgcactccagcctggcgacagag
cgagactccgtctca-3'
ERE-like sequences located in the 3'-monomers of consensus Alu family members. 
Progenitor 3' Alu-EREs   Found in these Alu consensus sequences 
AGGTtg-nnn-TGAgCc  AluSc, -Sg, -Sg1, -Sp, -Sq, -Sx, -Sz 
AGGctg-nnn-TGAgCc AluJb 
AGcTtg-nnn-TGAgCg AluYc5,  AluYd8 
AGcctg-nnn-TGAgCc AluYe5 
AGcTtg-nnn-TGAgtc AluYg6 
AGcTtg-nnn-TGAgCc AluY, -Ya1, -Ya4, -Ya5, -Ya8, -Yb3a1, -
Yb3a2, -Yb8, -Yb9, -Ybc3a, -Yc1, -Yc2, -
Yd2, -Yd3,  -Yd3a1, -Ye2, -Yf1, -Yf2, -Yi6    
AGGctg-nnn-TGAgCT AluJo 
A
B
Figure 2. The canonical 280-bp Alu sequence is composed of two monomers, derived from the 7SL RNA gene, separated by an adenosine rich
connector. The consensus AluSc sequence (A) contains an ERE-like sequence (red) identiﬁed in the 30 monomer of the element. A similar element
(blue) also occurs in the 50 monomer of the Alu element. The monomers are separated by an A-rich connector sequence (underlined). The previously
indentiﬁed Alu-Retinoic Acid Receptor response element (RARE) sequence is also indicated (purple). (B) Diverse ERE-like sequences located in the
30-monomers of classical Alu element family sequences are indicated. Mismatches from the consensus ERE sequence are indicated by lower case
letters.
Labeled Probe
(sequence)
ERE B68 D66
(GGTCAcaccGACC) C A G T c t g A C T G G ( ) C C A G T g t c A C T G G ( a)
Free Probe
ERα complex
Super Shift {
Antibody ERα ERα ERα Sp1 Sp1 Sp1
Lane 123456789
Figure 3. Electrophoretic mobility shift assay (EMSA) of ERa binding
to nonconsensus repetitive element ERE sequences. EMSA was per-
formed using HESC cell nuclear lysates plus recombinant ERa and
labeled consensus ERE probe (lanes 1–3) or repetitive DNA element
ERE sequences as probes: B68 (lanes 4–6) and D66 (lanes 7–9). An
ERa-containing complex bound to all three ERE sequences (arrow-
head, lanes 1, 4 and 7) and was conﬁrmed by supershift (bracket)
using a monoclonal antibody that recognizes ERa (lane 2). Speciﬁc
ERa-containing complexes were similarly shown by loss of bands for
B68 (lane 5) and D66 (lane 8) when anti-ERa antibody was added. The
nonspeciﬁc antibody recognizing Sp1 had no eﬀect on the ERa-
containing complexes bound to the classical ERE (lane 3) and B68
(lane 6), but displayed moderate eﬀects on complexes bound to D66
(lane 9), indicating that Sp1 may cooperate with ERa in binding to this
sequence. Mismatches from the consensus ERE sequence are indicated
by lower case letters and red font. Oligonucleotide sequences are
presented in Supplementary Table S1.
Nucleic Acids Research,2010, Vol.38, No. 7 2361mutagenesis of the MIRb-ERE (E2M) ablated enhancer
function, loss of the Alu-ERE element (E1M) similarly
resulted in  50% reduction in enhancer function of the
cloned locus. These data support a model in which both
repetitive element EREs contribute to B68-mediated
enhancer function in response to E2. The B68 locus
resides near the E2-responsive gene MREG and may
contribute to E2-dependent enhancement of this gene
(Table 2) (13,30).
D70 is a locus that contains two repetitive element
EREs (indicated by red font), the ﬁrst in an Alu
sequence and the second in a simple repeat (microsatellite)
sequence (Table 2). D70 resides near the E2-responsive
genes IER3 and PRR3. While the relative contribution
of each ERE to enhancer function was not assayed
(both are in repetitive DNA elements), the combined
eﬀects of the EREs clearly indicate strong enhancer func-
tions in response to E2 (Figure 4C).
Figure 5 displays the responses of additional cloned
loci that demonstrated moderate, weak, and zero
enhancer functions in luciferase reporter assays. The
D75 locus, near the E2-responsive gene ELOVL5,
has two ERE elements that reside within a non-LTR/
CR1 repetitive sequence (a LINE element, Table 2).
E2-dependent enhancer function of this locus was
observed (Figure 5A). The C31 locus, near the
E2-responsive gene SSR3, contains two ERE sequences
neither of which resides within repetitive DNA elements.
The C31 locus demonstrated E2-dependent enhancer
function in which both ERE sequences contributed to
overall transcriptional response and wherein the second
ERE proved necessary for a response (Figure 5B).
Additional repetitive and nonrepetitive ERE-containing
genomic sequences were tested for enhancer function,
revealing modest or no transcriptional enhancer function
for this set of cloned fragments (Figure 5C). Importantly,
Table 2. ChIP sites cloned and employed in luciferase reporter assays
ChIP
Name
ChIP
ID
a
Genomic Location 50 to 30EREs
at ChIP site
ERE sequence ERE in a
repetitive
element
Class E2-responsive
gene(s)
Distance to
TSS (kb)
A34 ER_57 chr1:109481687-109483388 ERE-1 TGGTCATGCTGATCT AluSp SINE CELSR2 <200
ERE-2 AGATCAGGTTGACCA No
B68 ER_393 chr2:216554841-216557061 ERE-1 AGGTTGCAGTGAGCC AluSp SINE MREG <50
ERE-2 GGGTCACACCGACCT MIRb SINE
C25 ER_586 chr3:147315203-147316986 ERE-1 AGGTCCTGATGACCA Cheshire A DNA
Transposon
PLOD2 <50
ERE-2 CTGTCACAGTGACTG Cheshire A DNA
Transposon
C31 ER_592 chr3:157742094-157743693 ERE-1 GGGTCAAGTTGACCT No SSR3 <50
ERE-2 AGGTTACTGTGACCT No
D54 ER_1007 chr5:173841513-173843928 ERE-1 GGCTCATGTTGACCT No MSX2 <250
ERE-2 AGGTCACTGTGACCC No
ERE-3 GAGTCAGGGAGACCT MIRb SINE
D66 ER_188 chr6:20318070-20319948 ERE-1 AGGTCAGTCTGACAT MIRb SINE E2F3 <200
ERE-2 TGGTCAGACTGACCT No
D70 ER_192 chr6:30826744-30828559 ERE-1 AGGTTGCAGTGAGCT Alu-Sp SINE IER3, PRR3 <50, <200
ERE-2 AGCTCAGCCTGACCC Simple
Repeat
(CAGCC)n
D75 ER_197 chr6:53436855-53439415 ERE-1 AGCCCAGTGTGACCT L2A Non LTR/CR1 ELOVL5 <200
ERE2 AGGACACTGTGACAT L2A Non LTR/CR1
F15 ER_1273 chr8:121154005-121156007 ERE-1 AGGTTGCAGTGAGCT Alu-Sc SINE DEPDC6 <100
ERE-2 AGGGCAGAGTGACCT No
ERE-3 CTGTCAGTTTGACCT No
F78 ER_656 chrX: 100548677-100550413 ERE-1 AGATCTCAGCGACCT No GLA <10
ERE-2 TTGTCACGGTGACCG No
G99 ER_1162 chr12:15259885-15261784 Single ERE AGGTCATGCTGCCCT No RERG <10
H59 ER_1446 chr14:22610298-2261233 ERE-1 AGGTCACCCTGCCCC No PRMT5 <50
ERE-2 AGGGCAAGGGGACCT No
I20 ER_698 chr15:73093906-73095506 ERE-1 AGGTCACTGTGTCTG No ULK3 <200
ERE-2 TGGGCACTGTGACTC AluJb SINE
ERE-3 AGGTTGCAGTGAGCT AluJb SINE
I47 ER_882 chr16:71520172-71521792 ERE-1 AGGTTGCAGTGAGCC AluSz SINE None
ERE-2 AGGTTGCAGTGAGCT AluSq SINE
J58 ER_745 chr20:45406674-45408274 ERE-1 AGGATACAGTGAGCT Alu SINE None
ERE-2 AGGCTACAGTGAGCT AluYe2 SINE
ERE-3 AGGTCACGGTGACTTN o
K31 ER_516 chr22:27539060-27540660 Single ERE AGTTCACCATAACCT AluSz SINE XBP1 <50
K32 ER_517 chr22:27544000-27546383 Single ERE GGGTCAGTTTGACTT No XBP1 <50
aID assignments from Hua et al., Mol. Syst. Biol. 2008.
ChIP names were assigned and correspond to previously published ChIP ID numbers (13). ERE sequences detected within 2kb of the center of each
locus are indicated and mismatches from the consensus ERE sequence are highlighted in red. For ERE sequences residing within a repetitive DNA
element, the type of element is indicated and its distance to the nearest E2-regulated gene is shown.
2362 Nucleic Acids Research, 2010,Vol.38, No. 7all of the cloned loci for these studies were ﬁrst identiﬁed
using ChIP-on-chip and ERa recruitment to all sites was
subsequently conﬁrmed using ChIP-PCR (Figure 1).
Despite conﬁdence that ERa is recruited to all of these
sites in response to E2, not all of these sites behaved as
transcriptional enhancers in reporter assays. It remains
possible that, in their native chromatin contexts with
appropriate regional cis- and trans-acting factors, these
elements could participate in E2-mediated transcriptional
responses. Alternatively, some of these weak/nonacting
loci may not serve as enhancer elements, in vivo, despite
their recruitment of ERa. Our reporter assays indicate
that arbitrarily sized genomic fragments, whether contain-
ing repetitive element EREs (i.e. I47 and K31), non-
repetitive element EREs (i.e. K32, F78 and G99), or
combinations of each (i.e. J58 and I20), will not
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Figure 4. Luciferase reporter assays of cloned genomic loci bound by ERa and displaying high enhancer activity in MCF7 cells. Genomic loci
(average length 776bp) containing one or more ERE sequences were cloned into a minimal promoter reporter construct driving luciferase gene
expression. Speciﬁc wild-type ERE sequences and mutated (i.e. E1M) ERE sequences are indicated above each clone being tested (repetitive element
EREs are indicated by red font, mismatches from the classical ERE sequence are indicated by lower case lettering, and mutated sequences were
changed to tttttt where indicated). Basal and E2-stimulated luciferase values are shown normalized to co-transfected b-galactosidase-expressing
plasmid. Clone D54 contains three ERE sequences and the third is in a repetitive element (see Table 2) which contributes to overall enhancer
function (A). B68 contains two ERE sequences both of which reside within repetitive DNA elements and both contribute to enhancer function (B).
D70 also contains two ERE sequences both of which reside within repetitive DNA elements (C). Values are the average of three experiments,
performed in triplicate, with SEM indicated. *P<0.01 comparing E2-treated wild type with E2-treated mutated reporter.
§P<0.01 comparing
E2-treated empty vector with E2-treated mutated reporter.
yP<0.01 comparing vehicle control-treated with E2-treated reporter.
Nucleic Acids Research,2010, Vol.38, No. 7 2363predictably demonstrate in vitro transcriptional
responses. Nevertheless, in aggregate, our data provide
evidence supporting a functional role for repetitive
DNA element EREs in ERa-mediated transcriptional
responses.
Loci with repetitive element EREs demonstrate
E2-dependent recruitment of SRC3
In response to estrogen exposure, functional EREs recruit
ERa-bound cofactors leading to enhanced or repressed
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Figure 5. Luciferase reporter assays of cloned genomic loci bound by ERa and displaying moderate, low, and no enhancer activity in MCF7 cells.
Genomic loci (average length 776bp) containing one or more ERE sequences were cloned into a minimal promoter reporter construct driving
luciferase gene expression. Speciﬁc wild-type ERE sequences and mutated (i.e. E1M) ERE sequences are indicated above each clone being tested
(repetitive element EREs are indicated by red font, mismatches from the classical ERE sequence are indicated by lower case lettering, and mutated
sequences were changed to tttttt where indicated). Basal and E2-stimulated luciferase values are shown normalized to co-transfected
b-galactosidase-expressing plasmid. D75 contains two repetitive element ERE sequences responsible for enhancer function (A). C31 contains two,
nonrepetitive element EREs that are functional (B). Additional ERE-containing clones with low or no enhancer function in luciferase assays are
indicated (C). Values are the average of three experiments, performed in triplicate, with SEM indicated. *P<0.01 comparing E2-treated wild-type
with E2-treated mutated reporter.
§P<0.01 comparing E2-treated empty vector with E2-treated mutated reporter.
yP<0.01 comparing vehicle
control-treated with E2-treated reporter.
2364 Nucleic Acids Research, 2010,Vol.38, No. 7target gene expression. In MCF-7 cells, an important
coactivator for the estrogen receptor is SRC3 (NCOA3)
(56). We performed ChIP-PCR using an antibody directed
against SRC3 and tested a selection of loci for hormone-
dependent recruitment of SRC3. Focusing principally on
loci which were shown to contain repetitive element EREs
that contribute to overall luciferase reporter activity
(Figures 4 and 5), we demonstrated greater than 2-fold
enhanced recruitment of SRC3 to these genomic sites in
response to estrogen when compared to vehicle-treated
cells (Figure 6). In addition, a control locus that did not
recruit ERa in our original studies (i.e. an ERa ChIP-
negative site), dubbed ERE(–), also did not recruit
SRC3 in response to estrogen. Interestingly, two loci
that were ChIP-positive using antibodies against ERa
but were inactive in our luciferase reporter assays, G99
and K31 (Figure 5C), were nonetheless sites in which E2
exposure resulted in the recruitment of SRC3 (Figure 6).
This observation suggests that the in vivo function of a cis-
regulatory element may not always be recapitulated using
assays in vitro, as mentioned above. In aggregate, the
hormone-dependent recruitment of both ERa and its
coactivator to repetitive element ERE-containing loci,
combined with functional studies in enhancer-reporter
assays, strongly support a role for repetitive element
ERE sequences in mediating ERa-dependent
transcriptional responses.
DISCUSSION
Recent location analysis for ERa-binding sites throughout
the human genome revealed evidence for substantial
long-range (>10kb) enhancer functions of the receptor
(13,14). Here, we reported the presence of full ERE
sequences at approximately half of all receptor-bound
loci. The absence of ERE sequences at many ERa-
bound genomic loci may reﬂect widespread tethering of
ERa to DNA targets via alternative transcription factors
[i.e. AP-1, Sp1 (10)] or the presence of widely divergent
ERa-binding motifs not detected using our motif search-
ing software. With regard to tethering to genomic targets
via protein–protein interactions with transcription factors
such as AP-1 and Sp1, there exist examples where the
estrogen receptor does not directly interact with DNA
sequences and others where ERE half-sites (i.e. AGG
TCA) enable estrogen receptor dimers to bind to DNA
while stabilized by a cooperating transcription factor
that is proximally bound to DNA (10). We, and others,
have demonstrated signiﬁcant enrichment of binding
site motifs for Sp1 and AP-1 at ERa-bound genomic
loci (13–15).
Although estrogen receptor dimers do not bind to
isolated half-ERE sequences in vitro (27), and receptor
dimerization is an important requisite for stable interac-
tion with target DNA sequences (44), there are reports
of receptor-mediated transcriptional responses at tandem
half-ERE sites (57,58). The extent to which such ERE
half-sites actually represent degenerate full EREs or com-
posite elements (cooperating with alternative transcription
factors in vivo) remains uncertain. It is noteworthy,
however, that our dataset of 1017 high-conﬁdence ChIP
sites is signiﬁcantly enriched for ERE half-sites when
compared to permutations of 1017 randomly selected
genomic sequences of the same size. We observed an
average of 2.2 half-EREs per ChIP site in our data set,
compared with an average of 1.1 half-EREs in the
randomly selected genomic sequences in our permutation
analysis (P=0.000004 from 100000 permutations). An
in vivo role for tandem ERE half-sites in ERa-mediated
transcriptional responses merits further study.
Unexpectedly, we observed that  20–30% of predicted
EREs reside within repetitive DNA sequences, principally
within the 30 monomers of Alu elements. We found only
one prior report of an Alu-ERE which was later demon-
strated to be nonfunctional (49,50). Our data indicate
considerable potential for repetitive element EREs, and
Alu-EREs in particular, to contribute to ERa-mediated
gene regulation. We tested several Alu-EREs, and EREs
that reside in alternative repetitive DNA elements, and
found that these contribute to enhancer function and are
located near E2-regulated genes.
Alu elements expanded extensively throughout primate
evolution and now occupy  10% of the human genome
(59). Their expansion throughout primate genomes
depended upon the transposition machinery encoded by
L1 retrotransposons, which are LINEs (long interspersed
elements) (52). Increasing evidence suggests that Alu
repeats are a source of diverse cis-regulatory elements
that regulate transcriptional initiation by RNA poly-
merase II (60–62). The Mader group recently reported
the presence of diverse Retinoic Acid Receptor (RAR)
response elements (RAREs) residing within the 50
monomers of Alu elements (Alu-RAREs) (63). There is
emerging evidence that E2 and RA can exert opposing
gene-regulatory eﬀects in breast cancer cells via
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Figure 6. ChIP-PCR conﬁrms estrogen-dependent recruitment of
SRC3 to repetitive element ERE-containing genomic loci. MCF7 cells
were treated with E2 (100nM) or vehicle (EtOH) for 45min. ChIP
was performed using antibodies against SRC3. Quantitative PCR
using genomic primers employed the 28S rRNA coding sequence as
internal reference. Shown are E2-treated values normalized to control
values. SRC3 was not recruited to an ERE-less and ERa ChIP-negative
locus dubbed ERE(–). Similar studies using genomic PCR primers for
the known E2-responsive gene TFF1 demonstrated rapid recruitment of
SRC3 to this enhancer region in response to E2. ChIP-PCR targeting
seven additional loci revealed E2-dependent enrichment (>2-fold)
of SRC3 at all sites. B68, D54, D66, D70, D75 and K31 are all
genomic loci that demonstrate repetitive element ERE sequences.
Values are the average of four experiments with SEM. Oligonucleotide
sequences are presented in Supplementary Table S1.
Nucleic Acids Research,2010, Vol.38, No. 7 2365receptor-mediated functions at neighboring cis-regulatory
loci (64). It is possible that some of these competing
gene-regulatory eﬀects occur via ERa and RAR function-
ing at neighboring 30 monomer Alu-ERE and 50 monomer
Alu-RARE sequences, respectively.
The expansion of Alu elements through Alu transposi-
tion may have distributed gene regulatory elements which
were later evolutionarily maintained (61,63). In particular,
this process may have contributed to the evolution
of novel E2-dependent gene regulatory networks. Given
the wide spectrum of regulatory sites present in Alus,
it remains important to include these loci in genome-wide
screening for transcription-factor response elements and
to consider these loci, which are often repeat-masked
and excluded, when performing studies pertaining to iden-
tiﬁcation of disease predisposition markers.
Our study comprises the largest collection of ERE
sequences published to date (Supplementary Table S3)
and is supported by evidence of in vivo ERa binding at
these sites. Our observations indicate that most ERa-
bound cis-regulatory elements are not consensus EREs
and that considerable deviation from the consensus
sequence can be permissive for receptor binding in vivo.
Low-aﬃnity interactions between transcription factors
and imperfect DNA binding sites have historically been
diﬃcult to detect in vivo. Recent data in yeast suggest that
such interactions may be more common, and provide
more biological impact, than had previously been sus-
pected (65). In addition, promiscuity of DNA-binding
sequences for a multitude of transcription factors in
mammals was recently suggested based upon a systems
approach to binding site detection in the mouse (66).
Together with our data, these observations suggest
numerous low-aﬃnity or transient transcription-factor–
DNA interactions occurring with diverse DNA sequences,
some of which may modulate transcriptional responses.
We found that 23% of ERE-containing sites have two
or more ERE-like sequences within 2kb of the center of
the ChIP site. This ﬁnding indicates that, in addition to
distantly spaced enhancers contributing to E2-mediated
transcriptional responses (28,35–39), some enhancer
regions may be composed of multiple, imperfect, ERE
sequences that provide additive or synergistic cis-
regulatory potential. This conclusion is supported by the
function of selected tandem EREs interrogated in our
luciferase reporter assays.
We found that the trinucleotide spacer sequences
between ERE half-sites is non-random at ERa-bound
loci, wherein C(A/T)G spacers are favored. This ﬁnding
held true even when repetitive element (i.e. repeat-masked)
EREs were excluded. It has been suggested that DNA
sequence serves as an additional ‘ligand’ for transcription
factor-containing protein complexes and can contribute to
receptor dimerization at imperfect EREs, alter receptor
conformation, and inﬂuence the net transcriptional
response of an ERE (67–71). Our data suggest that the
eﬀects of the ERE sequence on ERa-mediated transcrip-
tional responses may be inﬂuenced by the trinucleotide
spacer sequence, a hypothesis that we are currently
testing. In addition, the trinucleotide spacer sequence
may add predictive value when scoring sequences for func-
tional ERE motifs.
Full function of repetitive element and nonrepetitive
element EREs may depend upon the presence and distri-
bution of additional cis-regulatory elements which
work cooperatively in order to promote a transcriptional
response (28,36–39). Even high-conﬁdence ERa-bound
loci with nearly perfect consensus ERE sequences demon-
strate unpredictable cis-regulatory function in reporter
assays, a feature, which seems to reﬂect the inﬂuence
of surrounding DNA sequences. Such observations have
been noted by many authors when performing promoter–
reporter analyses using serially truncated promoter
sequences: function can be enhanced, lost, and then
enhanced again, with successive promoter truncations/
mutations. These ﬁndings are consistent with a model in
which DNA sequence and context will dictate the reper-
toire of inhibitory and activating co-factors, which, collec-
tively, determine the net transcriptional response of any
cloned DNA fragment. Whether genomic loci containing
multiple EREs represent stronger enhancers or repressors
of target gene expression, regulate multiple gene targets,
or recruit diﬀerent cofactor complexes when compared to
single ERE-containing loci remains to be studied.
The chromatin modiﬁcations that are necessary for
ERa-mediated transcriptional responses remain incomp-
letely described. We recently reported that the gene for the
variant histone H2A.Z is E2-responsive in MCF7 cells and
found that H2A.Z protein expression is an independent
predictor of breast cancer survival (13). We also showed
that H2A.Z is necessary for the E2-stimulated prolifera-
tive response in MCF7 cells. Gevry et al. (42) recently
demonstrated that H2A.Z is cyclically incorporated into
the enhancer and promoter regions of ERa gene targets
and is important to gene induction by the liganded
receptor. Combined, these data argue for a feed-forward
loop in breast cancer cells in which E2 stimulates H2A.Z
production, which in turn maximizes ERa-mediated
transcriptional responses.
Interestingly, H2A.Z is also highly enriched at both
glucocorticoid-inducible and constitutively nuclease acces-
sible glucocorticoid receptor-bound sites, suggesting a
shared chromatin remodeling mechanism modulating
the transcriptional responses of these nuclear hormone
receptors (72). Indeed, increasing evidence indicates that
the recruitment of H2A.Z to active promoters and
enhancers may represent a general mechanism permitting
or promoting gene activation in mammalian cells (73).
Given that a minority of predicted ERE sequences is
operative in any given cell type (36) and that diverse
repetitive element and nonrepetitive element ERE
sequences are capable of recruiting ERa in vivo, under-
standing which ERE sequences are functional in a given
cell type and milieu remains challenging. The cell-type-
speciﬁc determinants of ERE utilization remain to be
fully understood as are the mechanisms by which these
determinants are maintained or modulated by the
cellular milieu.
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